Article
Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) - 1 Nov 2020
Liu Xiaoke, Hong Lingzhi, Nilsson Monique, Hubert Shawna Marie, Wu Shuhong, Rinsurongkawong Waree, Lewis Jeffery, Spelman Amy, Roth Jack, Swisher Steven, He Yong, Jack Lee J, Fang Bingliang, Heymach John V, Zhang Jianjun, Le Xiuning
Abstract excerpt
BACKGROUND: Osimertinib is the treatment of choice for advanced EGFR-mutant non-small cell lung cancer (NSCLC). However, novel strategies to improve the duration of disease control are still urgently needed. Aspirin has been shown to decrease cancer incidence and improve outcomes in various malignancies. Therefore, we evaluated a cohort of patients who received osimertinib with or without concurrent use of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.